Abstract
BACKGROUND
Proton-pump inhibitors are effective at preventing the acid component of gastro-oesophageal refluxate from entering the oesophagus. It is not clear whether proton-pump inhibitors prevent duodenogastro-oesophageal reflux.
AIM
To measure oesophageal exposure to duodenogastro-oesophageal refluxate while on proton-pump inhibitors in patients with Barrett's oesophagus.
METHODS
Twenty-five patients (23 male) with Barrett's oesophagus underwent 24 h oesophageal pH and Bilitec 2000 monitoring while on omeprazole 40 mg/day (n = 19) or omeprazole 60 mg/day (n = 6). All patients were undergoing argon plasma ablation of their Barrett's epithelium as part of a clinical trial and the Bilitec measurements were only carried out after the ablation had been completed.
RESULTS
20 of 25 (80%) patients had a normal oesophageal pH profile. Fifteen of the 25 (60%) had abnormal oesophageal exposure to bile as measured by Bilitec 2000. Of the 20 patients who had a normal 24 h oesophageal pH profile, 11 (55%) had pathological exposure to bile in their oesophagus.
CONCLUSION
Complete acid suppression does not guarantee elimination of duodenogastro-oesophageal reflux.
TY - JOUR
T1 - Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus.
AU - Todd,J A,
AU - Basu,K K,
AU - de Caestecker,J S,
PY - 2005/4/9/pubmed
PY - 2005/7/6/medline
PY - 2005/4/9/entrez
SP - 969
EP - 75
JF - Alimentary pharmacology & therapeutics
JO - Aliment Pharmacol Ther
VL - 21
IS - 8
N2 - BACKGROUND: Proton-pump inhibitors are effective at preventing the acid component of gastro-oesophageal refluxate from entering the oesophagus. It is not clear whether proton-pump inhibitors prevent duodenogastro-oesophageal reflux. AIM: To measure oesophageal exposure to duodenogastro-oesophageal refluxate while on proton-pump inhibitors in patients with Barrett's oesophagus. METHODS: Twenty-five patients (23 male) with Barrett's oesophagus underwent 24 h oesophageal pH and Bilitec 2000 monitoring while on omeprazole 40 mg/day (n = 19) or omeprazole 60 mg/day (n = 6). All patients were undergoing argon plasma ablation of their Barrett's epithelium as part of a clinical trial and the Bilitec measurements were only carried out after the ablation had been completed. RESULTS: 20 of 25 (80%) patients had a normal oesophageal pH profile. Fifteen of the 25 (60%) had abnormal oesophageal exposure to bile as measured by Bilitec 2000. Of the 20 patients who had a normal 24 h oesophageal pH profile, 11 (55%) had pathological exposure to bile in their oesophagus. CONCLUSION: Complete acid suppression does not guarantee elimination of duodenogastro-oesophageal reflux.
SN - 0269-2813
UR - https://www.unboundmedicine.com/medline/citation/15813832/Normalization_of_oesophageal_pH_does_not_guarantee_control_of_duodenogastro_oesophageal_reflux_in_Barrett's_oesophagus_
L2 - https://doi.org/10.1111/j.1365-2036.2005.02406.x
DB - PRIME
DP - Unbound Medicine
ER -